121484-76-2

Basic information

• Product Name: 3-(3-benzyloxy-phenyl)-propionyl chloride
• Synonyms: 3-(3-benzyloxy-phenyl)-propionyl chloride
• CAS NO: 121484-76-2
• Molecular Weight: 274.747
• Mol File: 121484-76-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-(3-benzyloxy-phenyl)-propionyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-benzyloxy-phenyl)-propionyl chloride(121484-76-2)
• EPA Substance Registry System: 3-(3-benzyloxy-phenyl)-propionyl chloride(121484-76-2)

Safety Data

• Hazardous Substances Data: 121484-76-2(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 14755-02-3 3-hydroxycinnamic acid 
• 96251-92-2 (E)-3-(3-hydroxyphenyl)acrylic acid ethyl ester 
• 14755-02-3 3-hydroxy-trans-cinnamic acid 
• 100-44-7 benzyl chloride 
• 621-54-5 3-(3-hydroxyphenyl)-propanoic acid 
• 75849-10-4 ethyl 3-<3-(benzyloxy)phenyl>propanoate 
• 34708-60-6 3-(3-hydroxy-phenyl)propionic acid ethyl ester 
• 57668-34-5 3-(3-(benzyloxy)phenyl)propanoic acid 

Downstream Products

• 1380328-05-1 (R)-2-((2R,3R)-7-(3-(benzyloxy)phenyl)-3-((4-methoxybenzyl)oxy)heptan-2-yl)oxirane 
• 1380328-08-4 (R)-7-(2-(((2R,4S,5R,6R)-6-(4-(3-(benzyloxy)phenyl)butyl)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)methyl)-1,3-dithian-2-yl)-7-methyloct-1-en-4-ol 
• 1160697-43-7 ethyl 5-(3-(benzyloxy)phenyl)pentanoate 
• 1380327-88-7 (1R,3R,4R,5S,9R,13R)-9-(hydroxymethyl)-3-(4-(3-hydroxyphenyl)butyl)-4,16,16-trimethyl-2,6,10,17-tetraoxatricyclo[11.3.1.1^1,5]octadecane-7,11-dione 
• 75849-11-5 1-(benzyloxy)-3-(3-bromopropyl)benzene 
• 289034-17-9 C₁₈H₂₀O₂ 
• 1380328-03-9 (3S,4R)-8-(3-(benzyloxy)phenyl)-3-methyloct-1-en-4-ol 
• 946136-58-9 C₂₂H₂₇NO₂ 

Relevant articles and documents

SYNTHESIS AND CHEMISTRY OF AN IRON(III) TETRAPHENYLPORPHYRIN WITH A COVALENTLY-ATTACHED PHENOLATE TAIL

We report the synthesis of a phenolate-tailed iron(III) tetraphenylporphyrin, 1.The phenolate ligand is covalently-attached to the porphyrin ring and is coordinated to the iron(III) center.This phenolate ligand increases the rate of oxygen atom transfer to the metal center.

Improved and large-scale synthesis of 10-methyl-aplog-1, a potential lead for an anticancer drug

10-Methyl-aplog-1 (1), a simplified analog of tumor-promoting aplysiatoxin, is a potential lead for cancer therapy that exhibits marked and selective growth inhibitory effects against several human cancer cell lines and negligible tumor-promoting activity in vivo. However, more detailed evaluations of its toxicity and anticancer activity in vivo are hampered by supply problems associated with a non-optimal synthetic method. We here addressed this issue through a more practical and reliable synthetic method that afforded several hundred milligrams of 1 with high purity (>98%) in 23 steps from commercially available m-hydroxycinnamic acid with an overall yield of 1.1%. The utilization of two key reactions, substrate-controlled epoxidation and the oxidative cleavage of alkene with a free hydroxyl group, successfully reduced the existing five synthetic steps and markedly improved the handling of large amounts of intermediates. We also demonstrated for the first time that such an analog was synthetically accessible in reliable quantities and also that this large supply could advance in vivo trials for the treatment of cancer.

Discovery of azetidinone acids as conformationally-constrained dual PPARα/γ agonists

A novel class of azetidinone acid-derived dual PPARα/γ agonists has been synthesized for the treatment of diabetes and dyslipidemia. The preferred stereochemistry in this series for binding and functional agonist activity against both PPARα and PPARγ receptors was shown to be 3S,4S. Synthesis, in vitro and in vivo activities of compounds in this series are described. A high-yielding method for N-arylation of azetidinone esters is also described.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

Compounds of formula (I) are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus.